TransMedics: flying organs, shareholder returns
Will clinical and logistics scale produce durable per-share cash? Research checked 10 November 2026. Ordinary TMDX.NASDAQ share / USD, ISIN US89377M1099. Dated 9 November provider daily close $93.79, not live. Current public weighted Neutral shorter/Strong Buy longer; separate No Action – Keep Monitoring.
Q3 revenue $203.01m grew 41%, including 35% company-defined organic growth. Operating profit rose to $28.14m, while net profit fell to $17.07m as tax and financing costs rose. Operating margin 14% rounded versus 16% before. Nine-month operating cash of $77.85m less cash PPE of $52.15m leaves $25.70m before acquisition/financing/FX. PAD net cash of $5.31m is separate. R&D of $85.69m is operating expense, already reflected in cash flow. Noncash lease inception is not cash capex.
Cash of $492.96m and restricted cash of $18.44m are separate. Convertible principal of $460m matures 1 June 2028. Headquarters finance lease of $351.53m relates to Somerville, not aircraft; its accounting assumes a property purchase option priced at $374.59m through the end of 2027, rather than cash already spent or an unconditional aircraft bill.
Fixed 18 September 2027/2031 weighted endpoints of $96.68/$183.00 imply +3.08%/+95.12% cumulative price returns from $93.79, using unrounded targets. No future dividend cash assumed; no income uplift, before tax/fees, no reinvestment. Issuer has never paid dividends. Original dates are not rolled or annualized. Public delivery-rounded target math displays +3.10%/+95.12%; platform net-yield/reinvestment method is distinct.
Base: recurring cases and profitable network density. Bull: successful clinical expansion and Europe. Bear: pricing, alternative methods and underused fixed assets. Both kidney upside and clinical/aviation/reimbursement downside tails matter. One high-weight advisor’s $143 base/$255 bull/$40 bear September 2031 values are individual scenarios, not weighted stress endpoints. Fourteen correlated AI contributions disagree about terminal margins and funding.
July PAD announcement/August Q2 preceded September research; November Q3 came later. Guidance excluding PAD of $750–760m differs from inclusive guidance of $764–774m. PAD minority VIE consolidation does not establish outright legal aviation ownership. October IDE trial permissions are not commercial approval; kidney first human experience is expected in the second half of 2027. Twenty positive model steps do not promise rising market prices.
Research and primary sources
Related conversations
EP 40 | RxSight Stock Analysis: Will a Cataract Breakthrough Make Investors Rich?: Useful medical technology must translate into recurring commercial demand; different products and economics. Listen and read · ▶Watch on YouTube
Medtronic: A Smaller Company. A Stronger Investment? | EP027: Durable clinical demand versus cash and value left to shareholders; no stale forecast comparison. Listen and read · ▶Watch on YouTube
EP 38 | Boeing Stock Analysis: $745B Backlog. Where's the Cash?: Physical capacity, investment obligations and shareholder cash are different measures; organ transport differs from aircraft manufacturing. Listen and read · ▶Watch on YouTube
Last stock: Edenred Episode 42 (▶YouTube). Upstream manual-display QA remains open; primary checks are separate. Conditional research, not personalized instructions.
For the bigger picture, visit iPulse AI to explore our complete rankings of covered assets, discover the Strongest Buys, and see the research behind the ratings, all in one place. Primary research conducted through the iPulse AI platform by Future Edge Group. Like, comment and subscribe. We are publishing a new podcast every Monday through Friday. Stay tuned for the next podcast on Booking Holdings.
This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit